acut
respiratori
diseas
includ
common
cold
influenzalik
ill
croup
bronchiol
viral
pneumonia
caus
wide
varieti
viral
nonvir
agent
among
virus
rna
genom
tend
play
promin
role
particularli
among
immunolog
intact
individu
dna
virus
also
associ
respiratori
diseas
agent
describ
elsewher
text
characterist
virus
often
associ
respiratori
diseas
describ
briefli
three
distinct
type
influenza
virus
recogn
influenza
viru
influenza
b
viru
influenza
c
viru
base
antigen
differ
nucleoprotein
matrix
protein
three
virus
share
certain
characterist
includ
presenc
viral
envelop
contain
glycoprotein
import
viral
entri
egress
cell
segment
genom
standard
nomenclatur
influenza
virus
includ
influenza
type
place
initi
isol
strain
design
year
isol
hemagglutinin
ha
influenza
viru
mediat
attach
viru
suscept
cell
fusion
viral
envelop
cell
membran
antibodi
ha
neutral
viral
infect
main
protect
mechan
induc
infect
immun
neuraminidas
na
also
envelop
glycoprotein
play
import
role
releas
viru
cell
antibodi
na
also
inhibit
viral
replic
na
import
target
antivir
therapi
third
membran
protein
present
small
quantiti
virion
inhibit
amantadin
rimantadin
final
viral
structur
protein
matrix
nucleoprotein
np
import
target
cytotox
lymphocyt
ctl
parainfluenza
virus
also
envelop
virus
linear
singlestrand
rna
genom
four
distinct
human
serotyp
recogn
term
type
viral
envelop
glycoprotein
includ
hn
serv
viral
hemagglutinin
neuraminidas
f
mediat
fusion
viral
envelop
cell
membran
antibodi
either
hn
f
neutral
infect
antibodi
f
prevent
cell
cell
fusion
antibodi
hn
f
protein
play
role
resist
infect
passiv
transfer
monospecif
antisera
either
f
hn
protect
anim
vaccinia
virus
express
either
f
hn
induc
protect
immun
experiment
anim
anoth
envelop
singlestrand
rna
viru
import
respiratori
tract
respiratori
syncyti
rs
viru
rs
genom
encod
distinct
protein
includ
envelop
glycoprotein
f
g
g
attach
protein
mediat
bind
viru
host
cell
f
fusion
protein
allow
entri
viru
cell
promot
cell
cell
spread
f
g
viral
surfac
glycoprotein
appear
play
role
induct
neutral
antibodi
monoclon
antibodi
f
g
protein
neutral
infect
vitro
major
monoclon
antibodi
f
neutral
viru
small
proport
g
monoclon
antibodi
two
antigen
subgroup
rs
viru
denot
b
recogn
primarili
due
differ
g
glycoprotein
subgroup
b
subgroup
circul
popul
indic
gener
predomin
one
altern
year
suggest
infect
subgroup
virus
may
somewhat
sever
greater
frequenc
hospit
rs
viru
year
subgroup
virus
predomin
compar
subgroup
b
rhinovirus
member
picomaviru
famili
virus
nonenvelop
virus
linear
singl
strand
genom
posit
polar
rhinovirus
differenti
relat
enterovirus
rel
acid
labil
thermal
stabil
addit
rhinovirus
replic
effici
cell
cultur
lower
bodi
temperatur
human
known
natur
host
date
distinct
neutral
serotyp
rhinoviru
identifi
antigen
divers
result
amino
acid
sequenc
variat
four
recogn
antigen
site
surround
receptor
bind
site
major
human
rhinovirus
util
intracellular
adhes
receptor
major
bind
group
account
known
rhinoviru
serotyp
rhinoviru
serotyp
bind
refer
minor
receptor
group
virus
acut
respiratori
infect
one
commonest
problem
prompt
medic
consult
data
unit
state
collect
nation
health
interview
survey
suggest
ill
experienc
rate
ill
per
person
per
year
account
acut
condit
exclus
injuri
nation
morbid
survey
england
wale
conduct
gener
practic
acut
respiratori
infect
account
consult
approxim
entir
popul
consult
least
survey
year
acut
respiratori
infect
preschool
children
figur
respect
clinic
perspect
distinct
upper
lower
respiratori
ill
particularli
import
potenti
complic
higher
seriou
lower
respiratori
diseas
nevertheless
complic
upper
respiratori
ill
seriou
exampl
acut
sinus
damag
cell
line
lower
respiratori
tract
result
impair
oxygen
blood
thu
person
preexist
respiratori
cardiac
diseas
particular
risk
infect
assess
patient
present
doctor
respiratori
infect
cough
critic
symptom
minim
cough
associ
post
nasal
drip
accept
part
upper
respiratori
ill
signific
degre
cough
indic
ill
level
larynx
major
airway
fever
respiratori
rate
pule
use
marker
sever
ill
although
absenc
fever
older
person
exclud
seriou
respiratori
ill
older
person
lower
respiratori
infect
prompt
disturb
cardiac
rhythm
particularli
atrial
fibril
drive
patient
heart
failur
diagnost
terminolog
appli
respiratori
viral
infect
larg
syndrom
driven
reflect
pattern
symptom
sign
observ
term
often
use
determin
treatment
howev
import
first
consid
like
caus
poor
match
diagnost
term
common
use
etiolog
agent
although
syndrom
stronger
link
exampl
croup
parainfluenza
viru
link
tenuou
diseas
manag
must
take
account
like
specif
etiolog
associ
clinic
syndrom
virus
describ
follow
paragraph
realli
singl
definit
syndrom
common
cold
gener
term
taken
mean
acut
ill
rhiniti
variabl
degre
pharyng
predomin
associ
symptom
includ
nasal
stuffi
sneez
runni
nose
sore
throat
patient
often
report
chill
true
fever
unusu
presenc
lower
respiratori
tract
sign
symptom
indic
possibl
complic
headach
mild
malais
may
report
although
multitud
virus
may
associ
syndrom
pattern
symptom
associ
cold
appear
vari
significantli
agent
physic
find
nonspecif
commonli
includ
nasal
discharg
pharyng
inflamm
sever
diseas
higher
fever
may
seen
children
cold
gener
selflimit
total
durat
ill
approxim
day
aduh
recogn
complic
cold
includ
secondari
bacteri
infect
paranas
sinus
middl
ear
exacerb
asthma
chronic
bronchiti
emphysema
differenti
diagnosi
individu
present
typic
sign
symptom
extens
howev
presenc
addit
sign
symptom
part
clinic
descript
high
persist
fever
sign
respiratori
distress
lower
respiratori
tract
diseas
altern
diagnos
sought
allerg
caus
consid
individu
present
recurr
symptom
restrict
upper
respiratori
tract
evalu
patient
present
predominantli
pharyng
center
upon
differenti
bacteri
viral
nonbacteri
etiolog
presenc
nasal
symptom
conjunct
favor
viral
etiolog
pharyng
children
less
year
age
presenc
exud
suggest
bacteri
etiolog
exud
may
also
seen
adenoviru
infecti
mononucleosi
presenc
tender
palpabl
cervic
lymph
node
also
indic
bacteri
caus
rapid
test
group
streptococci
may
indic
case
signific
ill
etiolog
uncertain
routin
studi
bacteri
non
bacteri
pathogen
usual
obtain
otiti
media
commonli
thought
complic
upper
respiratori
tract
infect
though
mani
children
present
combin
upper
respiratori
symptom
concurr
earach
outset
infect
upper
respiratori
tract
associ
mucos
edema
interfer
normal
function
eustachian
tube
pressur
middl
ear
increas
give
rise
pain
reliev
tympan
paracentesi
though
procedur
rare
adopt
sinc
ill
resolv
spontan
without
ruptur
tympan
membran
much
debat
use
antibiot
treatment
acut
otiti
media
critic
factor
whether
secondari
bacteri
infect
establish
viru
caus
acut
respiratori
infect
predispos
otiti
media
mani
virus
recov
middl
ear
fluid
croup
clinic
distinct
ill
affect
children
age
three
ill
typic
begin
upper
respiratori
tract
symptom
rhinorrhea
sore
throat
often
mild
cough
two
three
day
cough
deepen
develop
characterist
brassi
bark
qualiti
similar
seal
bark
fever
usual
present
gener
child
may
appear
apprehens
comfort
sit
forward
bed
respiratori
rate
elev
contrast
bronchiol
usual
breath
per
minut
characterist
physic
find
croup
inspiratori
stridor
inspir
prolong
chest
wall
retract
may
observ
children
find
present
higher
risk
hospit
requir
ventilatori
support
rale
rhonchi
wheez
may
heard
physic
examin
sign
includ
bark
cough
inspiratori
stridor
aris
mostli
inflamm
occur
larynx
trachea
greatest
subglott
level
least
distens
part
airway
import
recogn
inflammatori
chang
note
throughout
respiratori
tract
croup
hypoxemia
detect
children
hospit
ill
fluctuat
cours
typic
viral
croup
child
may
appear
worsen
improv
within
hour
overal
virus
recov
croup
case
frequent
type
respiratori
ill
parainfluenza
virus
particularli
type
common
virus
respons
croup
account
case
viral
caus
croup
includ
respiratori
syncyti
viru
influenza
b
virus
rhinovirus
adenovirus
although
longer
endem
unit
state
measl
long
recogn
caus
sever
croup
parainfluenza
viru
type
influenza
virus
associ
sever
diseas
gener
clinic
present
croup
syndrom
due
individu
agent
similar
import
evalu
children
stridor
distinguish
croup
syndrom
potenti
seriou
caus
airway
obstruct
bacteri
epiglott
tracheiti
epiglott
acut
cellul
epiglotti
surround
structur
patient
present
acut
respiratori
distress
drool
bark
cough
croup
absent
bacteri
tracheiti
rel
rare
syndrom
mimic
croup
abund
purul
sputum
often
present
infecti
caus
stridor
includ
peritonsillar
retropharyng
abscess
diphtheria
noninfecti
caus
stridor
trauma
aspir
foreign
bodi
also
consid
acut
bronchiti
character
cough
often
expector
sputum
accompani
wheez
rale
auscult
distinct
asthma
difficult
though
link
recent
cold
respiratori
symptom
person
subject
recur
asthma
provid
basi
diagnosi
person
chronic
obstruct
pulmonari
diseas
experi
exacerb
ill
may
precipit
viru
infect
may
often
complic
secondari
bacteri
infect
acut
bronchiti
affect
person
age
though
effect
greater
young
children
elderli
person
predominantli
winter
ill
incid
increas
respiratori
virus
rsv
influenza
circul
commun
earli
stage
ill
may
primarili
relat
upper
respiratori
tract
develop
persist
cough
three
four
day
later
often
reason
prompt
consult
particularli
link
specif
viru
limit
research
caus
respiratori
exacerb
bronchiol
form
acut
bronchit
particularli
experienc
young
children
main
focu
infect
small
peripher
airway
syndrom
character
wheez
symptom
due
obstruct
expiratori
air
flow
onset
lower
respiratori
symptom
usual
preced
rhiniti
often
nasal
congest
discharg
sever
symptom
characterist
occur
day
later
cough
may
promin
initi
present
may
paroxysm
natur
presenc
absenc
cyanosi
reliabl
indic
degre
oxygen
physic
find
gener
confin
music
moist
rale
fever
frequent
present
begin
ill
onethird
hospit
infant
afebril
hospit
cours
variabl
infant
show
improv
day
peak
age
incid
bronchiol
two
month
age
case
occur
first
year
life
risk
hospit
sever
bronchiol
particularli
high
infant
congenit
heart
diseas
chronic
lung
diseas
immunodefici
addit
infant
born
prematur
less
week
age
time
present
also
risk
respiratori
syncyti
viru
caus
major
case
bronchiol
rs
viru
epidem
season
gener
novemb
februari
northern
hemispher
essenti
case
due
viru
overal
rs
viru
recov
threefourth
infant
admit
hospit
bronchiol
sever
respiratori
virus
associ
bronchiol
includ
rhinovirus
parainfluenza
virus
influenza
viru
mump
adenovirus
type
rel
uncommon
caus
may
associ
sever
diseas
includ
develop
chronic
form
bronchiol
refer
bronchiol
obliteran
differenti
diagnosi
diseas
character
expiratori
airflow
obstruct
infant
rel
small
pertussi
occasion
confus
bronchiol
howev
frequent
vomit
paroxysm
cough
would
clue
diagnosi
differenti
acut
infecti
bronchiol
initi
present
allerg
asthma
difficult
contribut
difficulti
assess
therapeut
intervent
diseas
anatom
defect
vascular
ring
caus
obstruct
airway
foreign
bodi
consid
strongli
especi
young
infant
gastroesophag
reflux
addit
consider
onset
influenza
typic
abrupt
ill
character
predomin
system
symptom
includ
fever
prostrat
myalgia
malais
nonproduct
couch
tend
predomin
late
ill
respiratori
symptom
may
rel
minim
particularli
earli
cours
includ
nasal
complaint
sore
throat
hoars
presenc
fever
cough
present
significantli
associ
higher
likelihood
isol
influenza
viru
nasopharyng
secret
involv
tracheal
epithelium
infect
complaint
burn
throat
substern
pain
may
seen
fever
usual
find
physic
exam
individu
influenza
may
exhibit
rhiniti
pharyng
conjunctiv
inject
tracheal
tender
chest
usual
clear
uncompl
case
acut
symptom
resolv
day
complet
recoveri
may
take
week
malais
easi
fatig
among
prolong
symptom
clinic
featur
influenza
b
viru
infect
similar
estim
cours
intens
influenza
epidem
healthi
adult
present
symptom
laboratori
evid
influenza
viru
infect
influenza
also
import
caus
acut
febril
ill
children
epidem
gener
symptom
influenza
similar
adult
although
children
may
higher
fever
febril
seizur
addit
complaint
myalgia
may
less
common
children
inabl
commun
symptom
howev
parent
may
note
lack
activ
lethargi
influenza
associ
otiti
media
influenza
viru
isol
middl
ear
fluid
affect
children
impact
influenza
elderli
popul
well
recogn
age
group
contribut
disproportion
hospit
death
influenza
epidem
howev
clinic
present
influenza
elderli
may
somewhat
blunt
rel
lower
fever
subtl
onset
symptom
particularli
elderli
individu
verbal
sign
influenza
may
low
grade
fever
lethargi
acut
respiratori
viral
ill
may
present
initi
influenzalik
pictur
includ
infect
adult
parainfluenza
respiratori
syncyti
virus
addit
influenza
viru
acut
infect
respiratori
syncyti
viru
may
complet
mimic
clinic
pictur
influenza
age
group
initi
stage
mani
bacteri
infect
may
resembl
influenza
clinician
must
awar
individu
initi
diagnos
acut
influenza
may
bacteri
ill
mening
overal
pneumonia
repres
end
spectrum
viral
infect
lower
respiratori
tract
includ
croup
bronchiol
tracheobronch
reactiv
airway
chang
develop
pneumonia
defin
develop
abnorm
alveolar
ga
exchang
accompani
inflamm
lung
parenchyma
often
associ
visibl
chang
chest
xray
abnorm
radiolog
studi
gallium
scan
although
consider
varieti
present
syndrom
depend
age
immunolog
compet
host
specif
viral
pathogen
certain
gener
featur
clinic
featur
primari
viral
pneumonia
adult
includ
cough
gener
nonproduct
although
product
frothi
pinkting
sputum
seen
sever
ill
individu
cyanosi
hypoxemia
typic
sever
primari
viral
pneumonia
physic
find
often
nonspecif
varieti
chest
xray
pattern
describ
includ
lobar
infiltr
typic
primari
viral
pneumonia
present
diffus
bilater
interstiti
infiltr
clinic
cours
primari
influenza
viru
pneumonia
often
progress
downhil
patient
die
era
prior
avail
mechan
ventil
mortal
healthi
adult
nonpandem
era
low
basic
present
viral
pneumonia
children
similar
somewhat
milder
clinic
present
vari
consider
specif
caus
agent
typic
includ
fever
lower
respiratori
tract
sign
symptom
difficulti
breath
nonproduct
cough
physic
find
wheez
increas
breath
sound
young
infant
may
present
apneic
episod
minim
fever
clinic
present
may
domin
associ
croup
bronchiol
frequent
present
major
case
viral
pneumonia
healthi
adult
due
associ
influenza
virus
addit
adenovirus
describ
caus
signific
outbreak
atyp
pneumonia
militari
recruit
viral
caus
pneumonia
otherwis
healthi
adult
includ
varicella
rsv
parainfluenza
viru
certain
geograph
region
clinician
may
encount
hantaviru
pulmonari
syndrom
hp
character
sever
pulmonari
dysfunct
day
prodrom
nonspecif
influenzalik
symptom
accompani
increas
hematocrit
due
hemoconcentr
thrombocytopenia
coagulopathi
children
respiratori
syncyti
viru
associ
largest
proport
viral
pneumonia
young
children
particularli
accompani
bronchiol
parainfluenza
virus
particularli
type
second
common
viral
caus
follow
influenza
b
virus
especi
period
epidem
preval
viral
etiolog
children
includ
adenovirus
measl
rare
rhinovirus
enterovirus
rubella
viru
herp
simplex
viru
bacteri
superinfect
common
complic
viral
lower
respiratori
tract
infect
particularli
adult
classic
histori
typic
episod
viral
ill
less
complet
recoveri
follow
day
later
recurr
fever
develop
cough
dyspnea
cxr
reveal
lobar
infiltr
clinic
cours
typic
bacteri
pneumonia
addit
combin
bacteri
viral
pneumonia
clinic
featur
common
adult
certain
virus
children
bacteri
superinfect
viral
pneumonia
occur
mani
bacteria
common
bacteria
respons
bacteri
pneumonia
complic
influenza
streptococcu
pneumonia
also
increas
rel
frequenc
staphylococci
hemophilu
influenza
differenti
viral
bacteri
form
pneumonia
children
clinic
ground
difficult
radiolog
criteria
alway
distinguish
entiti
well
howev
normal
infant
children
rs
parainfluenza
viru
pneumonia
bacteria
appear
play
import
role
routin
addit
antibacteri
agent
use
except
observ
develop
countri
mix
viral
bacteri
pneumonia
children
frequent
sever
individu
diminish
host
immun
may
develop
sever
lifethreaten
pulmonari
infect
entir
spectrum
rna
dna
virus
includ
virus
typic
caus
lower
respiratori
tract
diseas
normal
host
opportunist
viral
pathogen
dna
virus
includ
cytomegaloviru
cmv
herp
simplex
virus
hsv
varicella
zoster
viru
vzv
adenovirus
receiv
recognit
regard
antivir
agent
pathogen
describ
elsewher
book
rna
virus
also
receiv
increas
recognit
potenti
caus
signific
morbid
mortal
immun
compromis
rs
viru
well
recogn
caus
pneumonia
recipi
bone
marrow
solid
organ
transplant
typic
present
initi
upper
respiratori
infect
becom
relentlessli
progress
involv
lower
respiratori
tract
signific
hypoxia
oftentim
death
clinic
featur
nonspecif
mortal
report
despit
treatment
aerosol
ribavirin
parainfluenza
virus
piv
also
report
infrequ
lower
respiratori
tract
pathogen
solid
organ
bone
marrow
transplant
frequent
seen
four
serotyp
implic
influenza
may
also
caus
sever
diseas
transplant
recipi
subject
surviv
gener
gold
standard
specif
etiolog
identif
isol
cell
cultur
virus
respons
respiratori
diseas
readili
detect
cell
cultur
system
provid
appropri
care
exercis
collect
transport
specimen
specif
type
cell
use
depend
spectrum
virus
sought
vari
specif
clinic
situat
season
cultur
obtain
exampl
laboratori
might
routin
inocul
respiratori
cultur
rhmk
cell
year
round
add
cell
isol
parainfluenza
virus
cultur
obtain
spring
fall
ad
mdck
cell
facilit
isol
influenza
virus
winter
month
viral
cultur
highli
sensit
specif
also
advantag
isol
viru
avail
character
howev
best
circumst
result
test
avail
time
decis
regard
manag
therapi
individu
case
must
made
thu
consider
interest
develop
rapid
test
respiratori
viral
diagnosi
wide
use
test
base
immunolog
detect
viral
antigen
respiratori
secret
influenza
test
includ
directigen
flu
bectondickenson
flu
oia
biostar
quickvu
influenza
ab
test
quidel
corpor
addit
zstat
flu
zymetx
test
detect
presenc
viral
neuraminidas
enzymat
except
directigen
test
test
design
detect
influenza
b
modif
directigen
test
allow
detect
type
clinic
develop
report
sensit
test
relationship
cell
cultur
vari
somewhat
depend
natur
sampl
test
patient
deriv
publish
compar
data
current
avail
conclus
demonstr
superior
one
test
anoth
thu
decis
regard
specif
test
gener
made
basi
conveni
cost
familiar
oper
specif
techniqu
direct
antigen
detect
respiratori
secret
also
use
extens
rapid
diagnosi
respiratori
syncyti
viru
direct
indirect
immunofloresc
techniqu
use
mani
year
techniqu
advantag
microscop
examin
sampl
exfoli
nasopharyng
cell
allow
rapid
judgment
qualiti
sampl
howev
techniqu
labor
intens
requir
special
equip
highli
experienc
staff
perform
accur
reason
mani
laboratori
use
elisa
base
technolog
rapid
detect
sever
test
kit
current
avail
report
sensit
compar
cultur
antigen
detect
test
parainfluenza
viru
rhinovirus
current
commerci
avail
varieti
approach
direct
detect
viral
nucleic
acid
clinic
specimen
also
explor
rapid
diagnosi
includ
nucleic
acid
hybrid
polymeras
chain
reaction
amplif
pcr
pcr
particular
advantag
potenti
sensit
cell
cultur
possibl
detect
viru
sampl
virion
lost
viabil
addit
possibl
devis
multiplex
techniqu
singl
test
detect
number
differ
agent
howev
pcr
techniqu
labor
intens
technic
demand
also
requir
avail
special
laboratori
equip
thu
gener
supplant
antigen
detect
rapid
diagnosi
antivir
drug
amantadin
rimantadin
belong
class
inhibitor
antivir
effect
primarili
manifest
cell
cultur
inhibit
viru
uncoat
although
influenza
b
virus
use
similar
replic
strategi
differ
protein
nb
protein
appear
serv
role
ion
channel
viru
therefor
inhibitor
activ
influenza
virus
antivir
activ
two
member
class
amantadin
rimantadin
similar
drug
activ
strain
influenza
viru
varieti
cell
cultur
system
anim
model
cell
cultur
inhibitori
level
influenza
viru
rang
ugml
amantadin
ugml
rimantadin
strain
inhibit
concentr
ugml
less
sever
studi
evalu
effect
amantadin
treatment
influenza
virus
initi
pandem
studi
therapi
within
first
hour
ill
associ
decreas
durat
fever
hour
greater
proport
subject
consid
rapid
resolv
addit
treat
individu
rapid
decreas
individu
symptom
cough
sore
throat
nasal
obstruct
effect
treatment
recoveri
viru
nasopharynx
minim
studi
addit
studi
conduct
noninstitution
adult
children
infect
ahong
viru
treat
subject
approxim
hour
reduct
durat
fever
chang
symptom
treatment
amantadin
result
significantli
rapid
improv
small
airway
dysfunct
healthi
adult
uncompl
influenza
addit
trial
amantadin
therapi
perform
hlnl
virus
reappear
late
similar
result
earli
therapi
influenza
otherwis
healthi
adult
amantadin
shown
result
rapid
decreas
fever
higher
frequenc
subject
report
improv
symptom
hour
compar
placebo
addit
treat
subject
less
like
shed
viru
hour
second
studi
conduct
young
adult
infect
amantadin
therapi
associ
rapid
decreas
symptom
compar
aspirin
therapi
amantadin
treat
subject
also
decreas
viru
shed
studi
studi
therapi
acut
influenza
adult
rimantadin
shown
level
benefit
essenti
ident
seen
amantadin
treatment
adult
hlnl
influenza
result
improv
symptom
decreas
fever
reduc
viru
shed
compar
placebo
rimantadin
amantadin
directli
compar
random
trial
earli
therapi
efficaci
two
drug
essenti
ident
rimantadin
also
evalu
treatment
influenza
children
shown
reduc
level
viru
shed
earli
infect
compar
acetaminophen
variabl
effect
clinic
symptom
score
seen
one
studi
show
slight
decreas
score
fever
compar
acetaminophen
ill
rel
mild
show
signific
differ
studi
viru
shed
rel
prolong
receiv
rimantadin
resist
viru
shed
late
cours
ill
neither
amantadin
rimantadin
subject
extens
efficaci
evalu
highrisk
subject
one
placebocontrol
studi
carri
nurs
home
resid
show
rapid
reduct
fever
symptom
rimantadin
recipi
furthermor
physician
care
patient
blind
studi
drug
statu
prescrib
significantli
fewer
antipyret
antituss
antibiot
obtain
fewer
chest
xray
rimantadin
recipi
antivir
drug
resist
one
factor
limit
widespread
use
agent
amantadin
rimantadin
resist
virus
emerg
fairli
frequent
treat
individu
although
resist
infrequ
unexpos
individu
resist
viru
retain
full
pathogen
potenti
experiment
anim
caus
diseas
suscept
contact
influenza
viru
neuraminidas
membran
protein
whose
major
function
remov
termin
sialic
acid
residu
viral
receptor
host
cell
therebi
releas
viru
spread
cell
two
neuraminidas
inhibitor
zanamivir
oseltamivir
licens
therapi
acut
influenza
agent
broadli
activ
known
neuraminidas
subtyp
influenza
viru
well
influenza
b
virus
inhibitori
level
clinic
isol
rang
nmoll
cell
cultur
two
agent
similar
mani
respect
differ
zanamivir
administ
inhal
see
oseltamivir
administ
oral
inhal
zanamivir
initi
demonstr
effect
treatment
uncompl
influenza
otherwis
healthi
adult
initi
studi
conduct
europ
north
america
treatment
individu
laboratori
evid
influenza
viru
infect
within
hour
symptom
onset
associ
reduct
durat
ill
day
placebo
group
day
inhal
zanamivir
group
strike
differ
seen
analysi
restrict
individu
fever
enrol
enrol
within
hour
onset
symptom
differ
treat
placebo
group
approxim
day
treatment
within
hour
symptom
onset
also
associ
significantli
rapid
return
normal
activ
approxim
day
studi
differ
level
clinic
efficaci
subject
infect
influenza
influenza
b
virus
second
studi
conduct
southern
hemispher
treatment
individu
age
older
within
hour
symptom
onset
associ
differ
durat
ill
among
infect
subject
day
placebo
group
day
treat
group
similar
earlier
studi
signific
differ
effect
influenza
b
viru
treatment
associ
earlier
return
work
normal
activ
zanamivir
also
benefit
small
number
subject
enrol
studi
consid
rel
higher
risk
influenzarel
complic
rate
respiratori
complic
among
subject
reduc
placebo
group
treat
group
recent
third
studi
zanamivir
therapi
conduct
europ
show
reduct
durat
day
placebo
recipi
day
zanamivir
recipi
date
result
two
trial
oral
oseltamivir
therapi
acut
influenza
publish
first
trial
treatment
adult
older
within
hour
symptom
onset
result
decreas
durat
ill
day
day
decreas
sever
ill
addit
earli
therapi
associ
significantli
earlier
return
work
normal
activ
reduct
rate
complic
primarili
sinus
bronchiti
overal
rate
complic
placebo
group
reduc
receiv
oseltamivir
major
case
influenza
studi
due
influenza
virus
similar
result
report
treatment
studi
perform
concurr
canada
northern
europ
studi
earli
therapi
associ
reduct
durat
ill
among
infect
subject
reduct
durat
among
treat
within
hour
studi
neuraminidas
inhibitor
therapi
popul
report
abstract
form
earli
treatment
inhal
zanamivir
associ
reduct
durat
ill
elderli
highrisk
subject
slight
reduct
frequenc
patient
requir
addit
prescript
health
care
contact
approxim
reduct
rate
complic
use
oseltamivir
type
patient
also
report
result
reduct
durat
ill
fever
reduct
rate
complic
use
treatment
othewis
healthi
children
age
year
zanamivir
reduc
durat
ill
day
show
benefit
sever
ill
use
ancillari
medic
recent
administr
liquid
formul
oseltamivir
dose
mgkg
bid
result
reduct
median
durat
ill
children
age
oseltamivir
also
result
reduct
frequenc
complic
primarili
otiti
media
antibiot
prescrib
neuraminidas
inhibitor
interact
highli
conserv
residu
within
influenza
viru
neuraminidas
hypothes
antivir
resist
rel
limit
problem
virus
resist
vitro
antivir
activ
agent
isol
passag
ceu
cultur
analysi
virus
reveal
two
basic
mechan
resist
illustr
interact
role
viral
ha
na
bind
releas
infect
cell
mutat
within
catalyt
framework
na
abolish
bind
drug
describ
resist
mutat
na
may
associ
alter
characterist
enzym
significantli
reduc
activ
second
type
mutat
associ
cell
cultur
resist
virus
involv
mutat
receptor
bind
region
hemagglutinin
ha
mutat
associ
resist
neuraminidas
inhibitor
reduc
affin
ha
receptor
allow
cell
cell
spread
viru
absenc
na
activ
resist
virus
ha
mutat
exhibit
cross
resist
drug
cell
cultur
may
retain
suscept
anim
model
mani
virus
also
exhibit
reduc
virul
anim
howev
resist
virus
rare
isol
human
treat
neuraminidas
inhibitor
clinic
trial
date
well
character
resist
viru
report
far
recov
immunosuppress
child
receiv
zanamivir
preliminari
result
clinic
trial
immunolog
intact
individu
suggest
resist
virus
aris
infrequ
treatment
antivir
therapi
influenza
consid
adult
seek
treatment
within
first
hour
onset
ill
clinic
experi
use
inhibitor
extens
data
random
control
trial
neuraminidas
inhibitor
leav
littl
doubt
class
drug
effect
indic
except
neuraminidas
inhibitor
activ
influenza
b
viru
summar
data
present
earlier
benefit
expect
includ
approxim
day
reduct
durat
symptom
return
work
usual
activ
day
sooner
possibl
reduct
rate
complic
decis
whether
treat
individu
patient
involv
balanc
impact
benefit
individu
cost
therapi
sinc
part
drug
without
signific
risk
effect
treatment
initi
beyond
hour
window
onset
symptom
determin
like
low
healthi
adult
influenza
gener
selflimit
pose
signific
hurdl
effect
use
antivir
therapi
influenza
patient
must
correctli
identifi
ill
seek
medic
attent
interact
medic
system
achiev
form
diagnosi
prescrib
obtain
drug
within
short
time
frame
physician
issu
may
balanc
level
comfort
make
clinic
diagnosi
influenza
sinc
may
practic
confirm
case
microbiolog
current
state
technolog
certainli
evid
random
trial
neuraminidas
inhibitor
suggest
appropri
epidemiolog
support
clinic
diagnosi
influenza
made
confid
sinc
trial
subject
met
clinic
case
definit
rate
microbiolog
document
influenza
individu
physician
practic
therefor
need
adapt
strategi
best
suit
patient
popul
less
publish
inform
avail
regard
therapi
highrisk
individu
essenti
studi
support
util
amantadin
rimantadin
elderli
individu
cardiac
pulmonari
condit
although
appropri
dosag
reduct
drug
use
safe
studi
therapi
neuraminidas
inhibitor
conduct
much
larger
popul
includ
highrisk
subject
preliminari
analysi
studi
zanamivir
oseltamivir
suggest
drug
also
provid
benefit
high
risk
adult
result
rapid
recoveri
ill
day
howev
studi
abl
demonstr
convincingli
earli
treatment
influenza
individu
would
lead
reduct
subsequ
hospit
death
may
never
possibl
organ
prospect
random
control
trial
demonstr
effect
sinc
even
highrisk
subject
event
occur
rare
also
littl
inform
use
antivir
therapi
influenza
immunosuppress
individu
individu
sever
influenza
seen
beyond
hour
onset
symptom
immunosuppress
patient
may
exhibit
prolong
replic
influenza
viru
reason
imagin
may
greater
window
opportun
interven
antivir
drug
situat
data
base
specul
similarli
reason
imagin
sever
ill
patient
viru
posit
time
therapi
initi
might
benefit
even
hour
ill
sinc
adult
hospit
influenza
outsid
hour
window
extrem
relev
issu
fact
mani
individu
current
receiv
antivir
therapi
howev
never
possibl
success
complet
studi
evalu
question
definit
way
therapi
acut
influenza
children
also
receiv
rel
littl
attent
amantadin
licens
indic
us
although
data
summar
earlier
support
efficaci
rimantadin
well
howev
use
inhibitor
associ
particularli
high
rate
develop
resist
children
zanamivir
current
licens
use
individu
older
oseltamivir
licens
use
individu
year
age
older
although
describ
earlier
preliminari
evid
efficaci
younger
subject
report
studi
directli
compar
amantadin
rimantadin
shown
signific
differ
therapeut
efficaci
two
drug
howev
studi
directli
compar
efficaci
zanamivir
oseltamivir
inhibitor
neuraminidas
inhibitor
publish
result
individu
clinic
trial
suggest
influenza
viru
infect
avail
drug
similar
efficaci
addit
two
drug
activ
influenza
b
viru
zanamivir
oseltamivir
appear
similar
level
benefit
influenza
gener
although
neither
drug
evalu
extens
influenza
b
human
therefor
decis
regard
choic
individu
agent
individu
consid
side
effect
eas
use
concern
regard
develop
resist
cost
current
inform
regard
potenti
use
drug
two
class
combin
although
theoret
strategi
might
synergist
sinc
involv
two
distinct
antivir
target
ribavirin
broad
spectrum
antivir
agent
structur
similar
guanosin
cell
cultur
agent
antivir
activ
dna
rna
virus
includ
rsv
mechan
action
drug
unclear
may
multifactori
includ
alter
cellular
nucleotid
pool
inhibit
viral
mrna
format
perhap
reason
antivir
resist
rare
report
sindbi
viru
ribavirin
inhibitori
rsv
cell
cultur
level
ugml
aerosol
form
demonstr
effect
treatment
experiment
infect
varieti
anim
model
includ
cotton
rat
primat
sever
random
placebocontrol
trial
ribavirin
small
particl
aerosol
natur
occur
rs
viru
lower
respiratori
tract
diseas
normal
infant
infant
highrisk
underli
diseas
conduct
differ
measur
outcom
assess
studi
indic
benefici
effect
drug
viru
shed
clinic
ill
ribavirin
also
shown
benefit
administ
infant
requir
mechan
ventil
markedli
decreas
total
durat
ventil
hospit
compar
infant
receiv
placebo
howev
studi
use
random
prospect
well
retrospect
casecontrol
design
shown
benefici
effect
drug
reason
dispar
result
clear
may
involv
factor
choic
placebo
endpoint
use
studi
specif
patient
popul
involv
howev
doubt
efficaci
ribavirin
lead
reduc
enthusiasm
use
among
practition
variabl
result
treatment
trial
expens
drug
recent
prompt
reconsider
recommend
use
drug
current
recommend
regard
treatment
rsv
limit
treatment
select
infant
young
children
high
risk
seriou
rsv
diseas
specif
indic
includ
infant
congenit
heart
diseas
bronchopulmonari
dysplasia
cystic
fibrosi
chronic
lung
condit
prematur
infant
children
immunodefici
recent
transplant
recipi
patient
undergo
chemotherpay
malign
sever
ill
infant
receiv
mechan
ventil
high
risk
progress
optim
treatment
rsv
infect
immunocompromis
individu
unclear
ribavirin
therapi
rsv
pneumonia
patient
usual
success
use
rsvigiv
see
report
use
uncontrol
trial
dose
requir
gener
practic
adult
sever
rsv
lower
respiratori
tract
infect
transplant
recipi
usual
preced
sever
day
upper
respiratori
tract
symptom
one
option
would
preemptiv
therapi
develop
sever
diseas
preliminari
result
use
preemptiv
ribavirin
aerosol
ribavirin
plu
rsvigiv
encourag
need
confirm
control
trial
usual
dose
amantadin
treatment
healthi
adult
mg
oral
twice
day
day
amantadin
absorb
readili
gastrointestin
tract
excret
unchang
urin
averag
plasma
elimin
halflif
approxim
hour
young
adult
hour
elderli
consequ
lower
dose
mg
per
day
indic
older
adult
order
minim
risk
toxic
although
dose
also
associ
excess
side
effect
nurs
home
resid
major
side
effect
amantadin
minor
revers
cn
side
effect
insomnia
dizzi
difficulti
concentr
side
effect
may
troublesom
elderli
addit
amantadin
use
associ
seizur
individu
prior
seizur
disord
minor
gastrointestin
complaint
also
report
elimin
amantadin
almost
exclus
renal
signific
dosag
reduct
must
made
presenc
renal
impair
individu
complet
renal
failur
serum
half
life
long
day
small
amount
amantadin
remov
hemodialysi
cn
side
effect
amantadin
increas
drug
coadminist
anticholinerg
antihistamin
addit
trimethoprimsulphfamethoxazol
may
inhibit
tubular
secret
amantadin
increas
potenti
cn
toxic
known
signific
drug
interact
amantadin
howev
coadministr
amantadin
drug
cn
side
effect
could
conceiv
exacerb
effect
usual
therapeut
dose
rimantadin
also
mg
oral
twice
day
day
rimantadin
undergo
extens
metabol
liver
prior
excret
inact
metabolit
via
kidney
rel
littl
effect
moder
renal
hepat
insuffici
serum
level
rimantadin
howev
reduct
onehalf
normal
daili
dose
recommend
presenc
sever
dysfunct
known
drug
interact
significantli
affect
level
metabol
rimantadin
rimantadin
associ
consider
reduc
rate
cn
side
effect
compar
amantadin
compar
studi
long
term
administr
rate
cn
side
effect
significantli
differ
placebo
howev
recommend
dose
rimantadin
reduc
mg
per
day
elderli
similar
recommend
amantadin
popul
base
data
show
differ
clinic
trial
mg
mg
bid
dose
recommend
dose
oseltamivir
treatment
mg
oseltamivir
phosphat
twice
day
day
administr
drug
food
may
improv
toler
without
impact
drug
level
oseltamivir
rapidli
absorb
gastrointestin
tract
convert
liver
hepat
esteras
activ
metabolit
oseltamivir
carboxyl
metabolit
excret
unchang
urin
tubular
secret
serum
half
live
hour
dose
oseltamivir
reduc
mg
daili
individu
renal
impair
ie
creatinin
clearanc
less
mlmin
data
avail
regard
use
drug
individu
signific
level
renal
impair
likewis
inform
avail
regard
use
oseltamivir
individu
hepat
impair
preliminari
result
ongo
studi
elderli
otherwis
healthi
subject
suggest
dosag
adjust
necessari
group
clinic
signific
drug
interact
felt
unlik
oseltamivir
competit
hepat
esteras
extens
report
literatur
addit
oseltamivir
phosphat
carboxyl
metabolit
exhibit
low
protein
bind
oseltamivir
poor
substrat
cyp
isoenzym
hepat
glucuronyl
transferas
drug
elimin
tubular
secret
probenecid
increas
serum
level
activ
metabolit
approxim
twofold
howev
dosag
adjust
necessari
individu
take
probenecid
coadministr
cimetidin
amoxacillin
acetaminophen
effect
serum
level
oseltamivir
metabolit
zanamivir
bioavail
oral
rout
must
administ
topic
order
effect
studi
evalu
variou
mode
administr
determin
optim
dose
therapeut
use
mg
bid
x
day
drug
suppli
suppli
blister
pack
blister
contain
mg
zanamivir
mg
lactos
carrier
standard
dose
therefor
two
inhal
twice
day
use
diskhal
estim
approxim
mg
drug
actual
deliv
inhal
studi
radiolabel
carrier
suggest
diskhal
devic
use
healthi
adult
drug
would
distribut
throughout
respiratori
tract
rel
littl
initi
distribut
oropharynx
approxim
inhal
dose
adsorb
system
elimin
kidney
serum
half
life
hour
fate
drug
remain
respiratori
tract
unclear
presum
remain
respiratori
tract
expector
swallow
excret
fece
although
signific
increas
serum
half
life
seen
presenc
renal
failur
small
amount
drug
absorb
system
suggest
dosag
adjust
would
necessari
studi
pharmacokinet
drug
presenc
impair
hepat
function
report
zanamivir
exhibit
excel
safeti
profil
major
studi
perform
date
commonli
report
symptom
individu
treat
drug
includ
diarrhea
nausea
nasal
sign
symptom
occur
essenti
rate
zanamivir
placebo
recipi
one
studi
zanamivir
use
influenzainfect
subject
asthma
copd
frequenc
signific
chang
fevj
peak
flow
rate
higher
zanamivir
placebo
recipi
reason
individu
pulmonari
condit
readi
access
rapidli
act
bronchodil
use
zanamivir
event
drug
precipit
bronchospasm
low
system
exposur
drug
signific
drugdrug
interact
would
expect
addit
zanamivir
interact
cyp
seri
hepat
microsom
enzym
ribavirin
significantli
effect
treatment
rsv
deliv
topic
administ
system
therefor
drug
typic
administ
small
particl
aerosol
design
gener
particl
um
diamet
normal
dose
mgml
ml
water
administ
hour
treatment
durat
usual
day
depend
patient
clinic
cours
longer
durat
therapi
sometim
need
immunodefici
individu
higher
dose
shorter
durat
mode
therapi
drug
concentr
mgml
administ
period
three
time
daili
appear
equal
efficaci
standard
dose
plasma
level
vari
duratin
exposur
vari
ugml
pediatr
patient
contrast
level
respiratori
secret
much
higher
high
ugml
gener
drug
extrem
well
toler
revers
bronchospasm
report
rare
addit
drug
precipit
ventil
tube
may
creat
mechan
difficulti
depend
ventil
system
administ
system
ribavirin
result
anemia
preclin
studi
shown
terotogen
mutagen
addit
possibl
alter
intracellular
metabol
pool
ribavirin
immunosuppress
effect
experiment
antim
circumst
use
possibl
detect
ribavirin
environ
hospit
room
although
evalu
expos
health
care
worker
gener
detect
signific
level
ribavirin
blood
drug
detect
urin
expos
nurs
therefor
recommend
pregnant
women
advis
care
directli
patient
receiv
ribavirin
drug
administ
wellventil
room
current
inactiv
influenza
vaccin
consist
either
whole
viru
deterg
treat
splitproduct
subunit
hana
vaccin
licens
prevent
influenza
diseas
due
influenza
hlnl
influenza
b
virus
may
occur
singl
season
trival
vaccin
current
use
inactiv
vaccin
gener
growth
influenza
virus
embryon
hen
egg
virion
harvest
egg
allanto
fluid
inactiv
treatment
chemic
agent
betapropriolacton
partial
purifi
three
prepar
licens
use
whole
virion
vaccin
splitproduct
sub
virion
vaccin
gener
treatment
virion
deterg
purifi
subunit
vaccin
predominantli
contain
ha
na
protein
safeti
immunogen
type
vaccin
appear
compar
adult
random
placebocontrol
trial
modem
influenza
vaccin
demonstr
vaccin
well
toler
age
group
onequart
onehalf
vaccin
recipi
feel
discomfort
vaccin
site
hour
vaccin
percent
moder
sever
transient
local
pain
swell
system
symptom
malais
headach
myalgia
occur
low
rate
similar
placebo
system
complaint
may
common
individu
low
level
prevaccin
antibodi
guillainbarr
syndrom
report
receipt
influenza
vaccin
year
nation
immun
program
swine
influenza
estim
risk
acquir
gb
vaccin
nation
surveil
conduct
sinc
gener
identifi
increas
rate
syndrom
follow
vaccin
howev
slight
increas
risk
gb
seen
follow
vaccin
repres
excess
approxim
case
per
million
person
vaccin
inactiv
influenza
vaccin
shown
effect
prevent
influenza
random
cohort
studi
conduct
young
adult
level
protect
good
antigen
match
vaccin
epidem
virus
howev
antigen
related
vaccin
strain
epidem
strain
low
effect
inactiv
vaccin
effect
consider
lower
studi
suggest
vaccin
reduc
frequenc
sever
ill
greater
degre
frequenc
infect
young
adult
elderli
vaccin
healthi
adult
us
associ
decreas
absente
work
school
significantli
cost
save
rel
prospect
trial
protect
efficaci
conduct
high
risk
popul
one
recent
random
placebo
control
trial
elderli
popul
inactiv
vaccin
approxim
effect
prevent
laboratori
document
influenza
addit
numer
retrospect
casecontrol
studi
avail
document
effect
inactiv
influenza
vaccin
individu
recent
metaanalysi
publish
cohort
observ
trial
deriv
similar
estim
level
vaccin
efficaci
influenza
respiratori
ill
elderli
vaccin
protect
influenza
pneumonia
relat
hospit
elderli
even
accompani
decreas
allcaus
mortal
recent
conduct
medicar
demonstr
project
indic
vaccin
usag
benefici
effect
reduct
hospit
admiss
associ
laboratorydocu
influenza
b
infect
estim
among
elderli
person
us
influenza
vaccin
associ
direct
save
per
year
per
person
vaccin
also
suggest
vaccin
staff
chronic
care
facil
major
impact
mortal
elderli
resid
institut
prophylact
administr
amantadin
also
shown
prevent
influenza
due
hlnl
influenza
virus
major
studi
util
season
prophylaxi
studi
design
subject
begin
drug
begin
influenza
epidem
activ
continu
prophylaxi
durat
epidem
gener
week
level
protect
ill
adult
associ
microbiolog
document
influenza
viru
infect
report
hlnl
virus
virus
season
prophylaxi
also
effect
children
approxim
reduct
laboratori
confirm
ill
due
influenza
report
amantadin
also
evalu
prevent
influenza
individu
expos
index
case
studi
carri
famili
set
member
famili
receiv
prophylaxi
day
exposur
index
case
within
famili
studi
index
case
treat
amantadin
protect
famili
contact
note
howev
index
case
treat
amantadin
time
contact
receiv
prophylaxi
protect
seen
presum
gener
transmiss
amantadineresist
viru
set
prophylaxi
contact
amantadin
also
recommend
institut
set
nurs
home
never
control
clinic
trial
document
efficaci
approach
anecdot
report
signific
decreas
rate
influenza
case
initi
prophylaxi
support
concept
outbreakiniti
prophylaxi
key
featur
contribut
success
strategi
includ
rapid
recognit
respons
outbreak
isol
individu
receiv
treatment
amantadin
receiv
prophylaxi
similar
find
famili
set
failur
adher
practic
associ
develop
transmiss
resist
virus
within
institut
significantli
fewer
studi
prophylaxi
rimantadin
perform
howev
rimantadin
amantadin
directli
compar
season
prophylaxi
healthi
adult
level
protect
approxim
equal
rimantadin
also
evalu
contact
prophylaxi
famili
set
result
similar
describ
amantadin
contact
receiv
prophylaxi
rimantadin
result
signific
protect
index
case
also
receiv
therapi
rimantadin
protect
seen
rimantadineresist
virus
recov
prophylaxi
failur
control
studi
prophylact
use
rimantadin
elderli
highrisk
subject
report
neuraminidas
inhibitor
also
shown
effect
prevent
influenza
infect
ill
first
studi
evalu
use
zanamivir
season
prophylaxi
similar
strategi
use
evalu
inhibitor
studi
adult
random
receiv
either
zanamivir
mg
daili
inhal
placebo
begin
increas
influenza
activ
document
studi
site
continu
next
week
frequenc
respiratori
ill
associ
microbiolog
document
influenza
infect
reduc
placebo
group
zanamivir
group
result
protect
efficaci
endpoint
overal
rate
febril
respiratori
ill
irrespect
result
laboratori
test
reduc
placebo
group
zanamivir
group
oseltamivir
also
assess
season
prophylaxi
model
administr
oseltamivir
mg
daili
healthi
adult
durat
influenza
season
week
associ
reduct
overal
rate
respiratori
ill
associ
laboratori
confirm
influenza
infect
placebo
group
receiv
oseltamivir
recent
studi
oseltamivir
also
report
result
reduct
laboratori
confirm
influenza
vaccin
elderli
popul
live
nurs
home
chronic
care
facil
drug
also
evalu
prophylaxi
influenza
individu
exposur
index
case
also
report
one
studi
famili
one
individu
acut
influenzalik
ill
hour
durat
less
random
either
receiv
zanamivir
treatment
index
case
mg
bid
x
day
prophylaxi
famili
member
mg
qd
x
day
placebo
zanamivir
prophylaxi
associ
reduct
frequenc
one
contact
develop
influenza
famili
famili
receiv
placebo
famili
receiv
zanamivir
oseltamivir
also
test
famili
prophylaxi
similar
result
studi
index
case
receiv
treatment
howev
prophylaxi
famili
member
result
reduct
famili
experienc
ill
frequent
use
contact
prophylaxi
current
termin
outbreak
within
chronic
care
facil
sever
anectdot
report
success
use
zanamivir
fashion
addit
zanamivir
rimantadin
recent
compar
prospect
random
trial
outbreak
initi
prophylaxi
studi
use
zanamivir
result
fewer
case
seen
individu
random
receiv
either
rimantadin
influenza
outbreak
therapi
influenza
b
outbreak
note
major
instanc
failur
rimantadin
prophylaxi
associ
infect
rimantadin
resist
virus
effici
approach
prevent
influenza
yearli
administr
inactiv
influenza
vaccin
influenza
vaccin
administ
dose
ml
intramuscular
inject
year
age
older
younger
children
receiv
ml
adult
older
children
receiv
vaccin
deltoid
younger
children
gener
vaccin
anterolater
aspect
thigh
singl
dose
vaccin
requir
individu
previous
vaccin
experienc
prior
infect
relat
subtyp
two
dose
schedul
requir
children
less
receiv
influenza
vaccin
first
time
unprim
individu
use
second
dose
vaccin
otherwis
provid
addit
benefit
whole
viru
vaccin
avoid
children
year
age
associ
rel
higher
rate
fever
age
group
possibl
identifi
certain
individu
particularli
high
risk
influenza
relat
hospit
death
toward
program
vaccin
particularli
direct
current
recommend
target
group
influenza
vaccin
summar
tabl
specif
recommend
regard
target
group
review
year
updat
addit
individu
vaccin
recommend
includ
individu
health
care
worker
transmit
viru
other
high
risk
individu
infect
hiv
highrisk
individu
travel
area
influenza
epidem
occur
rel
easi
identifi
individu
alway
easi
deliv
vaccin
rate
influenza
immun
individu
older
us
risen
dramat
exceed
healthi
peopl
goal
state
howev
vaccin
coverag
rate
highrisk
individu
consider
lower
estim
approxim
antivir
drug
could
also
consid
prevent
certain
limit
circumst
moment
amantadin
rimantadin
licens
prevent
influenza
current
licens
antivir
strategi
current
would
effect
prevent
influenza
individu
administ
antivir
drug
durat
potenti
exposur
review
earlier
season
prophylaxi
strategi
basi
multipl
clinic
trial
demonstr
prophylact
activ
neuraminidas
inhibitor
fairli
obvious
practic
solut
gener
use
season
prophylaxi
consid
particularli
highrisk
individu
vaccin
would
expect
respond
vaccin
addit
season
prophylaxi
would
one
method
deal
situat
vaccin
includ
preval
epidem
strain
pandem
howev
might
expect
signific
logist
suppli
difficulti
use
antivir
prophylaxi
larg
scale
antivir
drug
also
use
shortterm
prevent
one
scenario
individu
vaccin
influenza
epidem
activ
alreadi
begun
circumst
reason
use
antivir
vaccin
immun
establish
immun
develop
quit
rapidli
follow
inactiv
vaccin
adult
gener
week
prophylaxi
vaccin
recommend
form
shortterm
prophylaxi
commonli
employ
exposur
either
famili
institut
set
describ
good
evid
support
effect
day
administr
antivir
contact
famili
member
develop
acut
influenza
part
strategi
would
appropri
set
highrisk
individu
within
famili
unusu
circumst
eg
vacat
import
life
event
strategi
could
consid
healthi
person
possibl
gener
transmiss
resist
influenza
virus
success
strategi
inhibitor
util
depend
also
use
inhibitor
treat
index
case
clear
whether
proscript
would
import
neuraminidas
inhibitor
well
common
use
short
term
prophylaxi
potenti
exposur
institut
set
situat
recipi
gener
alreadi
vaccin
constitut
group
vaccin
efficaci
may
ideal
potenti
consequ
influenza
demand
everi
addit
effort
taken
prevent
infect
surprisingli
littl
placebocontrol
data
support
use
outbreakiniti
prophylaxi
antivir
experi
famili
studi
variou
anecdot
report
suggest
may
benefit
approach
outbreak
initi
prophylaxi
use
essenti
institut
promptli
effect
sinc
influenza
spread
rapidli
institut
set
peak
outbreak
may
occur
day
recognit
index
case
therefor
program
util
stand
order
gener
success
rapid
diagnost
test
detect
influenza
may
also
quit
use
regard
sinc
clinic
present
influenza
popul
mute
difficult
differenti
respiratori
virus
rsv
rhinoviru
although
test
may
lower
sensit
cultur
aggreg
sensit
detect
least
one
posit
sever
sampl
adequ
allow
earli
recognit
respons
influenza
outbreak
individu
outbreak
recommend
durat
prophylaxi
week
one
week
beyond
last
document
case
reason
describ
famili
prophylaxi
isol
individu
receiv
treatment
inhibitor
individu
receiv
prophylaxi
inhibitor
import
reduc
gener
spread
resist
virus
altern
one
could
consid
treatment
one
class
agent
eg
neuraminidas
inhibitor
prophylaxi
class
eg
inhibitor
passiv
immun
receiv
consider
attent
treatment
prevent
respiratori
syncyti
viru
infect
strategi
base
earli
observ
passiv
transfer
antibodi
either
f
g
protein
prevent
infect
experiment
anim
also
effect
therapeut
although
therapeut
administr
antibodi
result
clinic
benefit
human
prophylaxi
passiv
antibodi
success
select
infant
initi
studi
util
select
pool
immunoglobulin
screen
high
titer
rs
viru
neutral
antibodi
refer
rsvigiv
respigam
administ
intraven
monthli
interv
rsv
season
activ
rsvigiv
shown
reduc
incid
rsvrelat
respiratori
hospit
infant
prematur
bronchopulmonari
dysplasia
current
recommend
dose
rsvivig
mgkg
iv
monthli
rsv
season
howev
administr
agent
involv
administr
larg
volum
fluid
children
cyanot
congenit
heart
diseas
receiv
rsvigiv
higher
incid
sever
advers
event
went
cardiac
surgeri
enhanc
mortal
thu
product
consid
contraind
infant
cyanot
congenit
heart
diseas
one
approach
circumv
problem
larg
volum
rsvivig
must
administ
use
human
monoclon
antibodi
high
rs
viru
neutral
titer
paluvizumab
synagi
human
monoclon
antibodi
direct
conserv
region
f
protein
hightit
neutral
activ
rsv
administ
intramuscularli
monthli
interv
prematur
infant
infant
chronic
lung
diseas
paluvizumab
shown
result
reduct
rsv
hospit
well
reduct
total
day
rsv
hospit
requir
icu
admiss
recommend
dose
agent
mgkg
intramuscularli
monthli
rsv
season
note
although
product
human
rather
human
monoclon
develop
antibodi
paluvizumab
report
infant
recipi
use
associ
signific
advers
event
success
passiv
antibodi
approach
suggest
right
circumst
prevent
sever
diseas
due
rs
viru
activ
immun
reason
goal
traumat
experi
enhanc
diseas
inactiv
rs
viru
vaccin
remain
major
obstacl
vaccin
develop
initi
attempt
develop
vaccin
rs
viru
involv
use
formalin
inactiv
viru
howev
vaccin
fail
provid
protect
field
trial
carri
despit
induc
high
level
rs
viru
antibodi
instead
subject
receiv
vaccin
experienc
enhanc
diseas
subsequ
rs
viru
infect
compar
other
receiv
control
vaccin
mechan
enhanc
remain
unknown
moment
commerci
avail
vaccin
prevent
rsv
although
sever
clinic
develop
cornerston
prevent
rsv
remain
institut
appropri
infect
control
practic
vaccin
current
avail
immunoglobulin
prophylaxi
current
recommend
limit
categori
patient
immunoglobulin
prophylaxi
consid
infant
children
less
year
age
chronic
lung
diseas
receiv
medic
manag
longterm
basi
eg
requir
medic
therapi
within
previou
month
benefit
group
mostli
shown
first
rsv
season
limit
data
effect
prophylaxi
second
season
exposur
anoth
group
consid
prophylaxi
infant
bom
week
gestat
earlier
children
gener
low
level
matern
antibodi
higher
risk
sever
diseas
children
congenit
cyanot
heart
diseas
immunodefici
could
also
theoret
benefit
prophylaxi
data
support
efficaci
either
prepar
condit
avail
sever
potenti
advantag
paluvisumab
rsvivig
prevent
rsv
infect
includ
rel
eas
conveni
im
compar
iv
administr
consider
smaller
volum
fluid
administ
fact
paluvisumab
human
bloodderiv
product
reason
paluvisumab
gener
favor
clinic
circumst
addit
rsvivig
contraind
children
cyanot
congenit
heart
diseas
howev
rsvivig
like
contain
polyclon
antibodi
varieti
pathogen
associ
decreas
rate
nonrsv
respiratori
hospit
thu
product
might
consider
infant
fluid
consider
paramount
alreadi
iv
access
exampl
infant
sever
combin
immunodefici
diseas
recipi
chronic
immunoglobulin
therapi
ig
immunoglobulin
data
random
control
trial
support
use
success
rate
ribavirin
alon
poor
approv
therapi
avail
time
tabl
group
increas
risk
influenza
complic
annual
vaccin
recommend
resid
nurs
home
chronic
care
facil
adult
children
chronic
disord
pulmonari
cardiovascular
system
includ
asthma
adult
children
chronic
metabol
diseas
includ
diabet
mellitu
renal
dysfunct
hemoglobinopathi
immunosuppress
includ
hiv
children
teenag
receiv
longterm
aspirin
therapi
women
second
third
trimest
preganc
